Last reviewed · How we verify

NCT06296836

Effect of Continuing Versus Holding Metformin During Hospitalizations.

Recruiting now Phase 4 Last updated 27 February 2025
What this trial tests

Phase 4 trial testing Metformin in Diabetes Mellitus, Type 2 in 300 participants. Currently enrolling.

Timeline
21 January 2025
Primary endpoint
31 March 2026
30 June 2026

Quick facts

Lead sponsorUniversity of Illinois at Chicago
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment300
Start date21 January 2025
Primary completion31 March 2026
Estimated completion30 June 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Illinois at Chicago

Who can join

Adults 18 to 110, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized study of continuing versus holding metformin during hospitalizations to internal medicine services to determine the effects on glucose control, acidosis, abdominal symptoms, length of stay, and mortality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

Other University of Illinois at Chicago trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06296836.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing